Australia News
Filter News
Found 6,988 articles
-
Immutep Reports Improving Results from INSIGHT-004 Trial
9/17/2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial
-
Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
9/17/2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study
-
Genetic Technologies Provides Update on COVID-19 Disease Severity Test Development
9/15/2020
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG, NASDAQ:GENE) (“Genetic Technologies” or the "Company") is developing a Polygenic Risk Score (PRS) test for COVID-19 which may enable an assessment of risk of an individual developing a serious disease should they contract the virus.
-
First patient dosed in SCENESSE® DNA Repair Program
9/15/2020
In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet radiation.
-
Starpharma to Webcast Live at Life Sciences Investor Forum September 17thCompany invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com
9/15/2020
Starpharma (ASX: SPL, OTCQX: SPHRY), based in Melbourne, Australia, today announced that Dr Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInvestorForum.com on September 17 th . DATE: Thursday, September 17 th TIME: 9:30 AM ET LINK: https://bit.ly/30GjErk If attendees are not able to join the event live on the day of the conference, an archived webcast will also be ma
-
First Patient Enrolled in AVITA Therapeutic’s Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo
9/14/2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the initiation of the pivotal study assessing the use of the RECELL® System to treat stable vitiligo with the enrollment of the first patient at Miami Derm
-
Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2
9/14/2020
New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19
-
Genetic Technologies Announces US Sales Have Commenced via Online Health Platform
9/11/2020
Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”) is delighted to announce that initial sales of its GeneType for Breast Cancer Risk Assessment have now commenced in the United States via an online health platform, elicity by InTeleLabs, an independent telehealth and personalised medicine company.
-
BioSpace Global Roundup, Sept. 10
9/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Opthea Appoints US-Based Non-Executive Director
9/10/2020
The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, are pleased to announce the appointment of Mr Daniel Spiegelman as an independent Non-Executive Director, who will also serve as Chair of the Company’s Audit and Risk Committee, effective from September 10, 2020.
-
Recce Pharmaceuticals Announces Positive & Concentration-dependent Efficacy of RECCE® Compounds Against COVID-19 in International Study
9/10/2020
Recce Pharmaceuticals Ltd (ASX: RCE), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on their international SARS-CoV-2 in vitro (organoid) studies undertaken by Path BioAnalytics Inc. (PBA) and The University of Tennessee Health Science Center (UTHSC).
-
CLINUVEL progresses innovative DNA Repair ProgramDrug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk
9/10/2020
CLINUVEL PHARMACEUTICALS LTD announced the progression of its drug SCENESSE® to treat the disease xeroderma pigmentosum.
-
Clarity Pharmaceuticals Announces the US FDA Grants Rare Paediatric Disease Designation to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma
9/9/2020
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to 64 Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma. Dr Alan Taylor
-
Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study
9/8/2020
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced positive efficacy data from a study of its induced pluripotent stem cell -derived Cymerus™ mesenchymal stem cells in a preclinical rodent model of idiopathic pulmonary fibrosis.
-
Beroni Group Receives First Commercial Order for its COVID-19 Test Kits from Japan
9/8/2020
Beroni Group, an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced that it received the first commercial order for its proprietarily developed SARS-CoV-2 Antibody Detection Kit from Forsitech Inc., a pharmaceutical trading company based in Japan.
-
Using gene therapy to edit embryos, sperm or eggs in order to improve health conditions in a child should not be conducted due to the unreliability of the science, as well as due to significant ethical and moral concerns.Those are the words found in new guidance established this week.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
BioSpace Movers & Shakers, Sept. 4
9/4/2020
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.
-
BioSpace Global Roundup, Sept. 3
9/3/2020
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.